Vida Ventures, the venture capital firm co-founded by CAR T pioneer Arie Belldegrun, has closed an oversubscribed $825 million fund, bringing the total amount of assets under management to more than $1.7 billion.
Tvardi Therapeutics Inc., a company targeting a protein essential to cancer cells' survival and immune evasion, closed a $74 million series B financing. The round will help it advance candidates through multiple midstage trial readouts in cancer and fibrosis, the Houston-based company said.
CEO Samantha Singer said Abata Therapeutics Inc. “spent a considerable amount of time finding the right indication” for its approach, which deploys autologous regulatory T cells (Tregs) made to express T-cell receptors (TCRs). That disease is progressive, non-relapsing multiple sclerosis (MS). “We’re going to be able to succeed with these patients where other options have failed,” she told BioWorld.
Biopharmas raising money in public or private financings, including: Bioasis, Biocytogen, Bioxcel, Century, Cyteir, Glycomine, Hutchmed, Immuneid, Orum, Strand, Vita.
Jacobio Pharmaceuticals Group Co. Ltd. has received a milestone payment of $20 million from Abbvie Inc. for dosing the first two patients in the U.S. for a global phase I/IIa study of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib, taking another step forward in the global SHP2 race.
PERTH, Australia – Immutep Ltd. announced a AU$60 million (US$45.1 million) capital raise via two tranches to progress two clinical programs of its lead immunotherapy, eftilagimod alpha, to registration studies.
Lenz Therapeutics Inc. emerged from stealth mode with $47 million in series A financing to fund its mission to bring a drug therapy to bear on farsightedness, a problem that affects much of humanity, at one point or another.
RSS
